CymaBay Therapeutics (NASDAQ: [[ticker:CBAY]]) has appointed Janet Dorling to serve as its chief commercial officer, the same position she held at antibiotics developer Achaogen. Her experience also includes time at Roche subsidiary Genentech. Newark, CA-based CymaBay is developing drugs for liver diseases. In June, the company reported preliminary Phase 2 results showing that its lead drug, seladelpar, did not beat a placebo in patients with nonalcoholic steatohepatitis, or NASH.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
